目的 观察夏荔芪胶囊联合左氧氟沙星治疗ⅢA型慢性前列腺炎的临床疗效。方法 选取2018年6月—2019年12月在濮阳市中医医院就诊的300例ⅢA型慢性前列腺炎，随机分为对照组和治疗组，每组各150例。对照组口服盐酸左氧氟沙星胶囊，2粒/次，2次/d。治疗组在对照组治疗的基础上口服夏荔芪胶囊，3粒/次，3次/d。1周为1疗程，两组均治疗6个疗程。观察两组的临床疗效，比较两组美国国立卫生研究院慢性前列腺炎症状指数（NIH-CPSI）和前列腺液量化积分的变化情况。结果 治疗后，治疗组的总有效率86.21%，对照组有效率65.07%，治疗组明显高于对照组，两组比较差异有统计学意义（P<0.05）。与治疗前相比，治疗后两组疼痛评分、尿路症状评分和对生活质量影响评分均显著降低（P<0.05）；治疗后，治疗组疼痛评分、尿路症状评分和对生活质量影响评分显著低于对照组（P<0.05）。治疗后，两组患者前列腺液量化积分均较治疗前显著降低（P<0.05）；治疗后，治疗组前列腺液量化积分显著低于对照组（P<0.05）；治疗组前列腺液量化积分前后差值显著大于对照组（P<0.05）。结论 夏荔芪胶囊联合左氧氟沙星治疗ⅢA型慢性前列腺炎可显著提高临床疗效，并能有效改善患者临床症状，安全性较高，具有很大的临床推广应用价值。

Objective To observe the therapeutic effect of Xialiqi Capsules combined with levofloxacin in treatment of ⅢA chronic prostatitis. Methods 300 Cases of ⅢA chronic prostatitis treated in Chinese Medicine Hospital of Puyang from June 2018 to December 2019 were selected and randomly divided into control group and treatment group, with 150 cases in each group. The control group were po administered with Levofloxacin Hydrochloride Capsules, 2 grains/time, twice daily. Patients in the treatment group were po administered with Xialiqi Capsules on the basis of the control group, 3 grains/time, three times daily. One course of treatment had 1 week, and both groups received 6 courses of treatment. The clinical efficacy of the two groups was observed, and the changes of chronic prostatic inflammation index (NIH-CPSI) and prostatic fluid quantitative score were compared between the two groups. Results After treatment, the total effective rate of the treatment group was 86.21%, and the effective rate of the control group was 65.07%. The effective rate of the treatment group was significantly higher than that of the control group, with statistically significant difference between the two groups (P<0.05). Compared with before treatment, pain score, urinary tract symptom score and life quality score of the two groups were significantly reduced after treatment (P<0.05). After treatment, the pain score, urinary symptom score and life quality score of the treatment group were significantly lower than those of the control group (P<0.05). After treatment, quantitative scores of prostatic fluid in both groups were significantly lower than that before treatment (P<0.05). After treatment, the quantitative score of prostatic fluid in the treatment group was significantly lower than that in the control group (P<0.05). The difference before and after quantitative integration of prostatic fluid in the treatment group was significantly greater than that in the control group (P<0.05). Conclusion Xialiqi Capsules combined with levofloxacin can significantly improve the clinical efficacy in treatment of ⅢA chronic prostatitis, and can effectively improve the clinical symptoms of patients with high safety, which has great clinical application value.

R983

河南省科技攻关计划项目（172102310306）；河南省中医药科学研究专项课题（2019ZY1042）